The Metformin Aneurysm Trial (MAT) An investigator initiated and conducted, multicentre, international, double-blinded, placebo-controlled, parallel-group, randomised controlled trial to determine the effect of metformin on abdominal aortic aneurysm (AAA) associated events, including AAA repair and AAA mortality (due to aneurysm rupture). (UK MAT)

Research summary

MAT is an international,multicenter,prospective,parallel-group,randomised,double-blind,placebo-controlled trial. The double-blind period will be preceded by a 6-week,single-blind (participants will remain blind),active run-in phase in which all potential participants will receive metformin sustained release (SR) with fortnightly dose increments. The aim of this run-in phase is to ensure the randomisation of participants who tolerate the treatment regimen and to increase the likelihood of high treatment adherence during long term follow-up. Randomised participants will receive study medication for an average of 3.5 years (up to 5 years).

Principal Investigator

Prof Regent Lee

Contact us

Email: crndirectdeliveryteam@ouh.nhs.uk

IRAS number

1005256